Fortress BiotechFBIO -8.61%44 Days Payable is 208.22 as of Mar. 2026, which is 65% below its 10-year median of 603.38. GuruFocus rates FBIO with a GF Score™ of 44/100 and a GF Value™ of $1.23 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 707 Biotechnology companies, Fortress Biotech ranks better than 71.57% on this metric.
The historical rank and industry rank for Fortress Biotech's Days Payable or its related term are showing as below:
FBIO'
s Days Payable Range Over the Past 10 Years
Min: 310.77 Med: 603.38 Max: 2590.77
Current: 310.77
During the past 13 years, Fortress Biotech's highest Days Payable was 2590.77. The lowest was 310.77. And the median was 603.38.
FBIO's Days Payable is ranked better than 71.57% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs FBIO: 310.77
Fortress Biotech's Days Payable
declined
from Mar. 2025 (566.30) to Mar. 2026 (208.22).
It may suggest that Fortress Biotechaccelerated paying its suppliers.
Fortress Biotech Days Payable Related Terms
Fortress Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Fortress Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fortress Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fortress Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (FBIO) has a Days Payable of 208.22 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fortress Biotech and its competitors. This is 65% below median its historical median of 603.38. Over the past decade, Fortress Biotech's Days Payable has ranged from 310.77 to 2,590.77. According to the industry distribution chart, Fortress Biotech ranks #201 out of 707 companies in the Biotechnology industry, placing it in the top 28.4%.
Is Fortress Biotech's Days Payable too high?
Fortress Biotech's current Days Payable of 208.22 is 65% below median its 10-year median of 603.38. Over the past 10 years, this metric has ranged from a low of 310.77 to a high of 2,590.77. The Biotechnology industry median Days Payable is 113.76. Fortress Biotech's value of 208.22 is 83% above this industry median. Based on the distribution chart, Fortress Biotech ranks #201 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Days Payable compare to PTHS and IBIO?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #201 out of 707 companies for Days Payable. This puts Fortress Biotech in the upper half of its industry. The industry median Days Payable is 113.76. Fortress Biotech's value of 208.22 is 83% above this benchmark. Historically, Fortress Biotech's own Days Payable has ranged from 310.77 to 2,590.77 over the past decade. While the company's 10-year median is 603.38 vs. the industry median of 113.76, Fortress Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortress Biotech's current Days Payable of 208.22 is 83% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fortress Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortress Biotech's current Days Payable is 208.22, which is 65% below median its own 10-year median of 603.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.23, compared to a current price of $2.74 — trading 122.8% above its estimated fair value. The current Days Payable is 208.22, which is 65% below median its 10-year median of 603.38 and 83% above the Biotechnology industry median of 113.76. Fortress Biotech's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Days Payable is 208.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (FBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of $2.74 is trading 122.8% above its estimated GF Value™ of $1.23.
GuruFocus considers Fortress Biotech to be Significantly Overvalued.
Key valuation signals for FBIO:
Days Payable: 208.22 (65% below median its 10-year median of 603.38)
GF Value™: $1.23 vs. price of $2.74 (122.8% above fair value)
Industry Position: 83% above the Biotechnology median (#201 of 707)
No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score
Get the complete analysis for FBIO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FBIO has been successfully added to your 
